AUCATZYL (Obecabtagene autoleucel)

Aucatzyl is an autologous anti-CD19 CAR-T therapy indicated for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL). Recommended total dose: 410 × 10⁶ CAR⁺ T cells, given in 2 split infusions (Day 1 and Day 10 ±2 days) after lymphodepleting chemotherapy. Boxed warnings for CRS (cytokine release syndrome), ICANS (immune effector cell-associated neurotoxicity), and secondary hematologic malignancies. No formal contraindications in the Prescribing Information. <a id="